← Eichor
Study identifier: NCT06617091 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

A Trial of a Gorilla Adenovirus Vectored Networked Epitopes Vaccine, Administered to Healthy Adults Living Without and With HIV.

Condition: HIV  ·  Sponsor: International AIDS Vaccine Initiative

PhasePhase 1
Planned participants120
Who can joinAll sexes, 18 Years to 50 Years
Healthy volunteersYes

About this study

A Phase 1 Randomized Double Blinded Placebo Controlled, Dose Ranging Trial, of a Gorilla Adenovirus Vectored Networked Epitopes Vaccine (GRAdHIVNE1 Vaccine), Administered to Healthy Adults Living without HIV and Living with HIV, in Southern Africa

This description comes directly from the study's public registry record.

Talk to the study team

Vincent Muturi-Kioi, MBChB  ·  +254-71-904-3151  ·  VMuturi-Kioi@iavi.org

Lebohang Molife, MBChB  ·  +27 76 866 7282  ·  LMolife@iavi.org

Always discuss trial participation with your own doctor first.

Locations (3)

AHRIMtubatuba, KwaZulu-Natal, South AfricaRecruiting
DTHFCape Town, Western Cape, South AfricaRecruiting
MutalaHarare, Harare, ZimbabweRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06617091